Nektar Therapeutics (NKTR) P/B ratio
Nektar Therapeutics (NKTR) trades at 6.7× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 7.9×. That is 152.2% higher than the 3.1× of fiscal 2024. Figures as of 18 Nov 2026, 10:46 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- P/B ratio today
- 6.7×
- P/B ratio, fiscal 2025
- 7.9×
- Change on fiscal 2024
- +152.2%
- Highest on record
- 106.0×fiscal 2017
- Lowest on record
- 0.8×fiscal 2023
- Fiscal years on record
- 102016–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Nektar Therapeutics P/B ratio, in more detail
Today's figure is 15.1% below the fiscal 2025 year-end.
Across the 10 fiscal year-ends on record (2016–2025), the highest was 106.0× in fiscal 2017 and the lowest 0.8× in fiscal 2023. Today's P/B ratio is higher than at 70% of the 10 fiscal year-ends on record; their median is 3.3×.
P/B ratio at each fiscal year-end
The last point is today's figure; the others are fiscal year-ends.
Nektar Therapeutics P/B ratio, year by year
| Fiscal year | P/B ratio | Change | Year ended | Share price at year-end | Book value per share |
|---|---|---|---|---|---|
| Today | 6.7× | — | $35.91 | — | |
| 2025 | 7.9× | 152.2% up | $42.28 | $5.32 | |
| 2024 | 3.1× | 287.7% up | $13.95 | $4.43 | |
| 2023 | 0.8× | 29.6% down | $8.40 | $10.34 | |
| 2022 | 1.2× | 68.3% down | $33.90 | $29.39 | |
| 2021 | 3.6× | 29.3% up | $202.65 | $55.61 | |
| 2020 | 2.8× | 4.8% up | $255.00 | $90.49 | |
| 2019 | 2.7× | 22.0% down | $323.85 | $120.47 | |
| 2018 | 3.4× | 96.7% down | $493.05 | $143.04 | |
| 2017 | 106.0× | 445.6% up | $895.80 | $8.45 | |
| 2016 | 19.4× | — | $184.05 | $9.47 | |
| 2015 | — | — | $252.75 | — | |
| 2014 | — | — | $232.50 | — | |
| 2013 | — | — | $170.25 | — | |
| 2012 | — | — | $111.15 | — | |
| 2011 | — | — | $84.00 | — | |
| 2010 | — | — | $192.75 | — | |
| 2009 | — | — | $139.80 | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.
How to read it
It compares the price with the accounting value of what the company owns net of what it owes, and matters most for banks, insurers and other balance-sheet businesses.
Nektar Therapeutics, figure by figure
- Nektar Therapeutics market cap
- Nektar Therapeutics revenue
- Nektar Therapeutics earnings
- Nektar Therapeutics earnings per share (EPS)
- Nektar Therapeutics P/E ratio
- Nektar Therapeutics P/S ratio
- Nektar Therapeutics free cash flow
- Nektar Therapeutics operating margin
- Nektar Therapeutics dividend
- Nektar Therapeutics shares outstanding
- Nektar Therapeutics total debt
- Nektar Therapeutics cash on hand
- Nektar Therapeutics total assets
- Nektar Therapeutics return on equity (ROE)
- Nektar Therapeutics return on invested capital (ROIC)
Nektar Therapeutics (NKTR) overview: price, valuation and scorecard
Nektar Therapeutics P/B ratio: questions and answers
What is Nektar Therapeutics's P/B ratio?
Nektar Therapeutics (NKTR) trades at 6.7× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 7.9×. That is 152.2% higher than the 3.1× of fiscal 2024.
Is Nektar Therapeutics's P/B ratio high or low compared with its own history?
Today's P/B ratio is higher than at 70% of the 10 fiscal year-ends on record; their median is 3.3×.
What are the highest and lowest P/B ratio figures on record for Nektar Therapeutics?
Across the 10 fiscal year-ends on record (2016–2025), the highest was 106.0× in fiscal 2017 and the lowest 0.8× in fiscal 2023.
How is Nektar Therapeutics's P/B ratio calculated?
The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B. For Nektar Therapeutics it is on record here for 10 fiscal years, 2016 to 2025.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/B ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Piotroski F-score: the nine tests and what they show
The Piotroski F-score is a 0–9 count of simple accounting tests a company passes: four on profitability, three on debt, liquidity and share issuance, two on operating efficiency. Joseph Piotroski's 2000 paper found that among cheap, high book-to-market stocks, high scorers went on to beat low scorers. It is a screen of financial health, not a valuation.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Nektar Therapeutics (NKTR) P/B ratio”, data as of 18 November 2026. https://funkfolio.com/stock/NKTR/pb-ratio
Underlying data: the company's filings with the SEC and Yahoo Finance.